When drug manufacturers have established key findings from Phase I and Phase II studies, such as  safe dosage, side effects and patient response to new therapeutic interventions, it’s time to move on to a Phase III trial.

Phase III studies can involve thousands of patients, across multiple clinical sites and across multiple global locations. With this brings several supply and demand-based challenges. One of these challenges relates to packaging and, more specifically, the design materials, operating forecasts and equipment needed to effectively and compliantly process and package clinical supplies.

To learn how one global pharmaceutical company overcame a number of packaging challenges arising from the scale and complexity of their Phase III clinical trial, download our case study by completing the form.

Click here to discover more about Almac Clinical Services